AstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate
January 19 2022 - 3:14AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that a combination of its Imfinzi
immunotherapy with tremelimumab antibodies showed an unprecedented
survival rate in liver-cancer patients.
The London-listed pharmaceutical company said results from its
Himalaya Phase III trial showed a single dose of tremelimumab added
to Imfinzi showed unprecedented survival in first-line unresectable
liver cancer. It said that 31% of patients were alive at three
years.
The company said that the combination--known as the STRIDE
regimen--also showed no increase in severe liver toxicity and that
no bleeding risk was observed.
Separately, AstraZeneca said Imfinzi plus chemotherapy reduced
the risk of death by 20% in first-line advanced biliary tract
cancer when compared with chemotherapy on its own.
"Positive results from the Topaz-1 Phase III trial showed
AstraZeneca's Imfinzi, in combination with standard-of-care
chemotherapy, demonstrated a statistically significant and
clinically meaningful improvement in overall survival and
progression-free survival versus chemotherapy alone as a 1st-line
treatment for patients with advanced biliary tract cancer," the
company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 19, 2022 02:59 ET (07:59 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024